Wuxi biologics' Hong Kong IPO of up to HK$3.98bn (US$511m) has drawn strong demand from investors, thanks to the company's high growth and the absence of exciting floats in the city this year. Books were multiple times covered at launch on the first day of bookbuilding last Thursday, with investors flocking to the IPO and many setting no price limits on their orders.
展开▼